The News:

Results from a massive, multi-center Phase III Randomized Controlled Trial (RCT) involving 4,000 participants show that specialized, standardized Ayurvedic formulations are therapeutically non-inferior to standard Iron Folic Acid (IFA) therapies in managing Iron Deficiency Anaemia.

Why it Matters:

This trial sets an important precedent for “Integrative Clinical Trials.” Subjecting traditional, plant-derived therapies to … [Read more](/content/landmark-trial-validates-integrative-medicine-for-anaemia/ "Landmark Trial Validates Integrative Medicine for Anaemia"/index.html)

The News:

The FDA has approved datopotamab deruxtecan-dlnk for patients with unresectable or metastatic triple-negative breast cancer who have received prior systemic therapies and are ineligible for targeted PD-1/ PD-L1 inhibitors.

Why it Matters:

TNBC remains a major clinical challenge due to the lack of estrogen, progesterone, or HER2 receptors. This TROP2-directed antibody-drug conjugate delivers … Read more

The News:

Data emerging from recent CRO industry forums and global clinical trial conferences highlights 2026 as a major inflection point for “Protocol Automation.” Advanced AI platforms are being routinely used to ingest unstructured PDF protocols and automatically configure functional electronic study databases (EDC).

Why it Matters:

Database build-out has historically represented one of the … [Read more](/content/the-rise-of-ai-powered-protocol-automation/ "The Rise of AI-Powered Protocol Automation"/index.html)

The News:

The FDA has granted accelerated approval to pivekimab sunirine-pvzy (Decnupaz) for adult patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive and historically difficult-to-treat hematologic malignancy.

Why it Matters:

Data from the pivotal CADENZA trial demonstrated a notable 69.7% complete remission rate in treatment-naïve cohorts. For an ultra-rare disease with poor … [Read more](/content/new-hope-for-ultra-rare-blood-cancers-decnupaz-approval/ "New Hope for Ultra-Rare Blood Cancers: Decnupaz Approval"/index.html)

The News:

The FDA has granted Breakthrough Device Designation to SPOT-MAS 10, a multi-omic blood test designed to detect cancer-associated signals across 10 different types, including lung, liver, and breast cancer.